295 related articles for article (PubMed ID: 29322286)
1. Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression.
Vasconcelos-Dos-Santos A; de Queiroz RM; da Costa Rodrigues B; Todeschini AR; Dias WB
J Bioenerg Biomembr; 2018 Jun; 50(3):175-187. PubMed ID: 29322286
[TBL] [Abstract][Full Text] [Related]
2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations.
Phillips RM; Lam C; Wang H; Tran PT
Adv Cancer Res; 2019; 142():23-62. PubMed ID: 30885363
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAc in cancer biology.
Ma Z; Vosseller K
Amino Acids; 2013 Oct; 45(4):719-33. PubMed ID: 23836420
[TBL] [Abstract][Full Text] [Related]
4. Roles of O-GlcNAc in chronic diseases of aging.
Banerjee PS; Lagerlöf O; Hart GW
Mol Aspects Med; 2016 Oct; 51():1-15. PubMed ID: 27259471
[TBL] [Abstract][Full Text] [Related]
5. New insights: A role for O-GlcNAcylation in diabetic complications.
Peterson SB; Hart GW
Crit Rev Biochem Mol Biol; 2016; 51(3):150-61. PubMed ID: 26806492
[TBL] [Abstract][Full Text] [Related]
6. Cross regulation between mTOR signaling and O-GlcNAcylation.
Very N; Steenackers A; Dubuquoy C; Vermuse J; Dubuquoy L; Lefebvre T; El Yazidi-Belkoura I
J Bioenerg Biomembr; 2018 Jun; 50(3):213-222. PubMed ID: 29524020
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.
Hanover JA; Chen W; Bond MR
J Bioenerg Biomembr; 2018 Jun; 50(3):155-173. PubMed ID: 29594839
[TBL] [Abstract][Full Text] [Related]
8. O-GlcNAcylation in Cancer Biology: Linking Metabolism and Signaling.
Ferrer CM; Sodi VL; Reginato MJ
J Mol Biol; 2016 Aug; 428(16):3282-3294. PubMed ID: 27343361
[TBL] [Abstract][Full Text] [Related]
9. Elevated O-GlcNAcylation stabilizes FOXM1 by its reduced degradation through GSK-3β inactivation in a human gastric carcinoma cell line, MKN45 cells.
Inoue Y; Moriwaki K; Ueda Y; Takeuchi T; Higuchi K; Asahi M
Biochem Biophys Res Commun; 2018 Jan; 495(2):1681-1687. PubMed ID: 29196265
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal regulation between O-GlcNAcylation and tribbles pseudokinase 2 (TRIB2) maintains transformative phenotypes in liver cancer cells.
Yao B; Xu Y; Wang J; Qiao Y; Zhang Y; Zhang X; Chen Y; Wu Q; Zhao Y; Zhu G; Sun F; Li Z; Yuan H
Cell Signal; 2016 Nov; 28(11):1703-12. PubMed ID: 27515988
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance.
Liu Y; Cao Y; Pan X; Shi M; Wu Q; Huang T; Jiang H; Li W; Zhang J
Cell Death Dis; 2018 May; 9(5):485. PubMed ID: 29706631
[TBL] [Abstract][Full Text] [Related]
12. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease.
Tramutola A; Sharma N; Barone E; Lanzillotta C; Castellani A; Iavarone F; Vincenzoni F; Castagnola M; Butterfield DA; Gaetani S; Cassano T; Perluigi M; Di Domenico F
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3309-3321. PubMed ID: 30031227
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ALDH2 by O-GlcNAcylation contributes to the hyperglycemic exacerbation of myocardial ischemia/reperfusion injury.
Liu B; Wang J; Li M; Yuan Q; Xue M; Xu F; Chen Y
Oncotarget; 2017 Mar; 8(12):19413-19426. PubMed ID: 28038474
[TBL] [Abstract][Full Text] [Related]
14. O-GlcNAcylation in women's cancers: breast, endometrial and ovarian.
Trinca GM; Hagan CR
J Bioenerg Biomembr; 2018 Jun; 50(3):199-204. PubMed ID: 29127647
[TBL] [Abstract][Full Text] [Related]
15. Role of O-linked N-acetylglucosamine modification in diabetic nephropathy.
Gellai R; Hodrea J; Lenart L; Hosszu A; Koszegi S; Balogh D; Ver A; Banki NF; Fulop N; Molnar A; Wagner L; Vannay A; Szabo AJ; Fekete A
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1172-F1181. PubMed ID: 27029430
[TBL] [Abstract][Full Text] [Related]
16. Conditions Inducing Excessive O-GlcNAcylation Inhibit BMP2-Induced Osteogenic Differentiation of C2C12 Cells.
Gu H; Song M; Boonanantanasarn K; Baek K; Woo KM; Ryoo HM; Baek JH
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29315243
[TBL] [Abstract][Full Text] [Related]
17. Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease.
Gatta E; Lefebvre T; Gaetani S; dos Santos M; Marrocco J; Mir AM; Cassano T; Maccari S; Nicoletti F; Mairesse J
Pharmacol Res; 2016 Mar; 105():186-97. PubMed ID: 26816085
[TBL] [Abstract][Full Text] [Related]
18. Potential role of O-GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitro.
Zhang N; Chen X
Biotechnol Appl Biochem; 2016 Nov; 63(6):841-851. PubMed ID: 26333304
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAcylation: a bridge between glucose and cell differentiation.
Sun C; Shang J; Yao Y; Yin X; Liu M; Liu H; Zhou Y
J Cell Mol Med; 2016 May; 20(5):769-81. PubMed ID: 26929182
[TBL] [Abstract][Full Text] [Related]
20. O-GlcNAcylation affects β-catenin and E-cadherin expression, cell motility and tumorigenicity of colorectal cancer.
Harosh-Davidovich SB; Khalaila I
Exp Cell Res; 2018 Mar; 364(1):42-49. PubMed ID: 29391154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
